Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Innovent’s Phase 3 TED Treatment Success in China
Innovent Biologics announced the successful achievement of the primary endpoint in the phase 3 registrational study, RESTORE-1, of IBI311 in China. This recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody marks a pivotal advancement in the treatment of thyroid eye…
Dr. Arshad Khanani Joins Ophtea as Chief Medical Advisor
Opthea Limited announced Dr. Arshad M. Khanani, MD, MA, FASRS, as its new Chief Medical Advisor. Dr. Khanani, renowned in retina specialization and clinical research, brings a wealth of expertise from his tenure at Sierra Eye Associates and his academic…
MACUSTAR Extends Systematic AMD Research
The MACUSTAR consortium, led by the Department of Ophthalmology at the University Hospital Bonn (UKB), is extending its Europe-wide clinical study on age-related macular degeneration (AMD). The primary focus of the extension is to garner further insights into the intermediate…
FDA Approves XDEMVY for Demodex Blepharitis
Tarsus Pharmaceuticals has received FDA approval for XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% to treat Demodex blepharitis, making it the first and only FDA-approved treatment directly targeting Demodex mites, the underlying cause of the condition. The approval was based on the…
Study Finds Key Genes Linked to Primary Open-Angle Glaucoma
In a recent study published in Nature Communications, researchers from Mass Eye and Ear, led by Ayellet Segrè, Ph.D., alongside Janey Wiggs, MD, Ph.D., conducted an extensive investigation that merged findings from a large cross-ancestry genome-wide association study meta-analysis of…
Lupin Launches Bromfenac Ophthalmic Solution in the US
Lupin Limited announced the launch of Bromfenac Ophthalmic Solution, 0.075%. The product has received the green light from the United States Food and Drug Administration (U.S. FDA), marking a crucial milestone for the company’s expansion in the American pharmaceutical market.…
Opthea Completes Enrollment for Wet AMD Trial
Opthea has reached a significant milestone in its quest to combat wet age-related macular degeneration (AMD) with the completion of patient enrollment in the COAST phase 3 pivotal clinical trial. The trial investigates sozinibercept (OPT-302), a promising vascular endothelial growth…
Dry Eye Treatment & Cyclosporine and Side Effect in Dogs
Dry eye disease (DED), also known as keratoconjunctivitis sicca (KCS), is a common disorder of the eye affecting millions of people around the world. The prevalence of DED ranges from 5% to 33% worldwide with increased prevalence among adult women…
What Is Corneal Collagen Cross-Linking?
The world of ophthalmology is constantly evolving, with innovative treatments and procedures emerging to address a wide range of eye conditions. One such cutting-edge treatment, corneal collagen cross-linking (CXL), has gained significant attention for its role in managing keratoconus, a…
FDA Warns Against Infection Risks from Copycat Eye Drops
The U.S. Food and Drug Administration (FDA) is warning consumers against the purchase and use of South Moon, Rebright, or FivFivGo eye drops due to the potential risk of eye infection. These products, identified as copycats, pose a danger as…